| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH does not have a specific biological target. It is a chemical building block used in peptide synthesis. The final glycopeptide product may have biological activity, but the protected building block itself is not pharmacologically active.
|
|---|---|
| ln Vitro |
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH is a protected amino acid derivative used as a building block in solid-phase peptide synthesis for the preparation of glycopeptides. It contains an Fmoc-protected amino group and a peracetylated galactosamine (GalNAc) moiety attached to the serine hydroxyl group. Its activity is chemical, not biological.
|
| ln Vivo |
No in vivo activity data are documented for Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH in the provided sources. As a chemical building block, it is not evaluated for pharmacological effects in animal models. Its primary use is in peptide synthesis.
|
| Enzyme Assay |
In vitro assays are not typically performed for Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH, as it is a chemical reagent rather than a drug. Its purity and identity can be confirmed by HPLC, NMR, and MS. Its suitability for use in peptide synthesis can be assessed by standard peptide coupling reactions.
|
| Cell Assay |
In vitro cell-based assays are not typically performed for Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH. As a chemical building block, its primary use is in peptide synthesis. Its effects on cell viability or metabolism are not standard assays for this compound.
|
| Animal Protocol |
In vivo animal studies are not typically conducted for Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH. As a chemical building block, its safety has likely been assessed for handling in the laboratory, but it is not a therapeutic agent.
|
| ADME/Pharmacokinetics |
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH has a molecular weight of 656.64 and a molecular formula of C32H36N2O13. It should be stored at -20°C, protected from moisture and light. It is soluble in DMF and other organic solvents commonly used in peptide synthesis.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH in the provided sources. As a research compound, it is intended for laboratory use only. Standard laboratory safety practices should be followed when handling this compound.
|
| Additional Infomation |
Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH is a protected amino acid derivative used in solid-phase peptide synthesis. It is a building block for the synthesis of glycopeptides. The Fmoc group is removed under basic conditions during peptide synthesis. It is for research use only.
|
| Molecular Formula |
C32H36N2O13
|
|---|---|
| Molecular Weight |
656.63384
|
| Exact Mass |
656.222
|
| Elemental Analysis |
C, 58.53; H, 5.53; N, 4.27; O, 31.67
|
| CAS # |
120173-57-1
|
| PubChem CID |
10908465
|
| Appearance |
Solid powder
|
| LogP |
2.432
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
47
|
| Complexity |
1140
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O=C(N[C@H](C(O)=O)CO[C@@H](O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O)[C@@H]1NC(C)=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
ORICVOOXZDVFIP-VOZJJELXSA-N
|
| InChi Code |
InChI=1S/C32H36N2O13/c1-16(35)33-27-29(46-19(4)38)28(45-18(3)37)26(15-42-17(2)36)47-31(27)43-14-25(30(39)40)34-32(41)44-13-24-22-11-7-5-9-20(22)21-10-6-8-12-23(21)24/h5-12,24-29,31H,13-15H2,1-4H3,(H,33,35)(H,34,41)(H,39,40)/t25-,26+,27+,28-,29+,31-/m0/s1
|
| Chemical Name |
(2S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
|
| Synonyms |
Fmoc-Ser[GalNAc(Ac)3-α-D]-OH; Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH; OVN73571; OVN-73571; OVN 73571;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~152.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5229 mL | 7.6146 mL | 15.2293 mL | |
| 5 mM | 0.3046 mL | 1.5229 mL | 3.0459 mL | |
| 10 mM | 0.1523 mL | 0.7615 mL | 1.5229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
